[Information provided by:
ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]
|NCT01821443 : A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)|
|Ages||Min: 18 Years Max: N/A|
- Pathologically (histologically or cytologically) proven diagnosis of a
non-hematopoietic malignancy other than small cell lung cancer and germ cell
malignancy within 5 years of registration. If the original histologic proof of
malignancy is greater than 5 years, then pathological confirmation is required (e.g.
from extra- or intracranial disease).
- Patients with 1-10 measurable brain metastases on a diagnostic-quality
contrast-enhanced magnetic resonance imaging (MRI) scan obtained within 30 days prior
- Patients with ?10 cc largest tumor volume, and ?15 cc total tumor volume.
- History/physical examination within 30 days prior to registration.
- If an open biopsy is performed, the patient must be at least one week post biopsy.
This requirement does not apply to patients who undergo stereotactic biopsies.
- Age ?18 years.
- Karnofsky performance status ?70 (RTOG recursive partitioning analysis (RPA) Class I &
- Minimum pre-treatment oNCF score ?70.
- Patients must provide study-specific informed consent prior to study entry.
- Women of child-bearing age must have a negative, quantitative serum pregnancy test ?14
days prior to study entry, or have a documented reason why such a test is not
necessary (e.g. history of tubal ligation).
- Patients must be able to speak and read English fluently (required for the use of
online NCF testing).
- Clinical (e.g. multiple cranial nerve deficits in the absence of obvious radiographic
disease to explain symptoms) or radiographic evidence of leptomeningeal disease.
- Patients with measurable brain metastasis(es) resulting from small cell lung cancer
and/or germ cell malignancy
- No documentation of prior cytotoxic or other therapy for malignancy if such therapy
was previously received. Note: This does not apply to patients with synchronous
metastases at initial diagnosis.
- Contraindication to MR imaging, such as implanted metal devices or foreign bodies,
severe claustrophobia, or contraindications to contrast agent administration.
- Estimated glomerular filtration rate (eGFR) <60 within 6 weeks prior to registration.
- Prior radiation therapy to the brain.
- Severe, active co-morbidity, defined as follows:
- Unstable angina, and/or congestive heart failure requiring hospitalization within
the last 6 months.
- Transmural myocardial infarction within the last 6 months.
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness
requiring hospitalization, or precluding study therapy at the time of
- Uncontrolled, clinically significant cardiac arrhythmias.
- Radiologic or clinical evidence of hydrocephalus, or history of previously
- Women of childbearing potential and male participants who are sexually active and not
willing/able to use medically acceptable forms of contraception; this exclusion is
necessary because the radiation treatment involved in this study is potentially
|Links||Permanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01821443
| Link to official Clinicaltrials.gov listing